Company news
Outlook Therapeutics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
April 7, 2025
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
February 28, 2025
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
February 19, 2025
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
February 13, 2025
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
February 3, 2025
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
January 30, 2025
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
January 22, 2025
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
January 21, 2025
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
January 15, 2025
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
December 26, 2024
Outlook Therapeutics® Streamlines Operations
December 12, 2024
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
December 3, 2024
Outlook Therapeutics® Announces Executive Leadership Transition
December 2, 2024
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
November 26, 2024
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
November 5, 2024
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment
October 16, 2024
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
September 15, 2024
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
September 12, 2024
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
September 3, 2024
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 2, 2024
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update
August 13, 2024
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 11, 2024
Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast
August 6, 2024
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
July 29, 2024
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
July 7, 2024
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
June 10, 2024
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
May 27, 2024
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
May 14, 2024
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
May 12, 2024
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
May 8, 2024
Outlook Therapeutics® to Present at the Retina World Congress 2024
May 1, 2024
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
April 28, 2024
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
April 14, 2024
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
March 21, 2024
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
March 17, 2024
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
March 11, 2024
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
February 13, 2024
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
January 30, 2024
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
January 22, 2024
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
December 21, 2023
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010
December 18, 2023
Outlook Therapeutics® Announces Strategic Organizational Realignment
December 5, 2023
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010
November 26, 2023
Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe
November 13, 2023
Outlook Therapeutics® Provides Update on Type A Meetings with FDA
November 1, 2023
Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference
October 31, 2023
Outlook Therapeutics® Requests Type A Meeting With FDA
September 28, 2023
Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 4, 2023
Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
August 29, 2023
Calls
Decks
- Q3 2026 Earnings Presentation
Earnings · 16 slides · Aug 14, 2026
- Technical Presentation (January 2025)
Technical · 13 slides · January 2025
- Corporate Update (August 2021)
Corporate update · 21 slides · Aug 3, 2021